Advertisement


Matthew J. Ellis, PhD, MB, BCh, on Breast Cancer: Results of the FALCON Trial

2016 ESMO Congress

Advertisement

Matthew J. Ellis, PhD, MB, BCh, of the Baylor College of Medicine, discusses phase III study findings on fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced disease. (Abstract LBA14)



Related Videos

Gynecologic Cancers

Jung-min Lee, MD, on Ovarian Cancer: Study Results on Checkpoint Kinase Inhibitors

Jung-min Lee, MD, of the National Cancer Institute, discusses findings of a phase II study of the cell cycle checkpoint kinase inhibitors LY2606368 and prexasertib monomesylate monohydrate in sporadic high-grade serous and germline BRCA mutation-associated ovarian cancer. (Abstract 855O)

Skin Cancer

Christian U. Blank, MD, PhD, on Melanoma: Initial Data From the OpACIN Trial (German Language Version)

Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses in German study findings on neoadjuvant ipilimumab plus nivolumab in patients with palpable stage III melanoma. (Abstract LBA39)

Solid Tumors
Palliative Care

Philippe Rochigneux, MD, on Solid Tumors: Use of Chemotherapy Near the End of Life

Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses his findings on the high rates of chemotherapy used at the end of life for metastatic solid cancer, especially in young patients treated in high-volume centers without a palliative care unit. (Abstract 1300O)

Gynecologic Cancers

Susana N. Banerjee, MBBS, PhD, on Ovarian Cancer: Results of the CORAL Trial

Susana N. Banerjee, PhD, MBBS, of The Royal Marsden NHS Foundation Trust, discusses phase II findings on abiraterone in patients with recurrent epithelial ovarian cancer. (Abstract LBA33)

Breast Cancer

Melanie Royce, MD, PhD, on Breast Cancer: Results From the BOLERO-4 Trial

Melanie Royce, MD, PhD, of the University of New Mexico, discusses phase II study findings on first-line everolimus plus letrozole in patients with ER+, HER2− advanced breast cancer. (Abstract 222O)

Advertisement

Advertisement




Advertisement